Assessing the Threat: Public Health

This chapter describes three methods for assessing the impact of transfusion-transmitted infections on public health. In order of increasing precision and labor intensity, these tools are: A blueprint for a structured, qualitative inventory and report, describing the relevant characteristics of the emerging agent, which helps to make ad hoc decisions and which identifies gaps in our knowledge. Two more sophisticated “off the shelf” methods for the quantitative analysis of threats to blood safety are mentioned: the Biggerstaff-Petersen model and the European Up-Front Risk Assessment Tool (EUFRAT). The Biggerstaff-Petersen model estimates the number of potentially infectious donations, while EUFRAT also takes into account the components prepared from donations and the efficacy of various mitigating interventions. Finally examples of quantitative studies of specific agents are mentioned: a donor-recipient transmission study and a cost-benefit modeling study. For this kind of analysis, no standardized recipe is available.

[1]  B. Biggerstaff,et al.  Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City , 2002, Transfusion.

[2]  M. Kretzschmar,et al.  Modelling the risk of transfusion transmission from travelling donors , 2016, BMC Infectious Diseases.

[3]  V. Hoad,et al.  Re‐evaluating the residual risk of transfusion‐transmitted Ross River virus infection , 2016, Vox sanguinis.

[4]  M. Kretzschmar,et al.  Estimating the transfusion transmission risk of Q fever , 2014, Transfusion.

[5]  V. Sambri,et al.  The Chikungunya epidemic in Italy and its repercussion on the blood system. , 2008, Blood transfusion = Trasfusione del sangue.

[6]  I. Ushiro-Lumb,et al.  Hepatitis E virus in blood components: a prevalence and transmission study in southeast England , 2014, The Lancet.

[7]  S. Ritchie,et al.  Implications of Dengue Outbreaks for Blood Supply, Australia , 2013, Emerging infectious diseases.

[8]  J. Desenclos,et al.  Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007 , 2008, Transfusion.

[9]  M. Janssen,et al.  Cost‐effectiveness of the screening of blood donations for hepatitis E virus in the Netherlands , 2017, Transfusion.

[10]  B. Biggerstaff,et al.  Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002 , 2003, Transfusion.

[11]  M. Verweij,et al.  Are there ethical differences between stopping and not starting blood safety measures? , 2017, Vox sanguinis.

[12]  Mark Penney,et al.  Prevalence of lymphoreticular prion protein accumulation in UK tissue samples , 2004, The Journal of pathology.

[13]  J. Linehan,et al.  Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic , 2013 .

[14]  M. Koppelman,et al.  Detection of parvovirus B19 DNA in blood: Viruses or DNA remnants? , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[15]  G. Bonsel,et al.  The PROTON study: profiles of blood product transfusion recipients in the Netherlands , 2010, Vox sanguinis.

[16]  M. Ison,et al.  Current practices and evaluation of screening solid organ donors for West Nile virus , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[17]  S. Görg,et al.  Look‐back study on recipients of Parvovirus B19 (B19V) DNA‐positive blood components , 2015, Vox sanguinis.

[18]  G. Bonsel,et al.  Cost‐effectiveness of additional blood screening tests in the Netherlands , 2012, Transfusion.

[19]  M. Kretzschmar,et al.  Estimating the risk of dengue transmission from Dutch blood donors travelling to Suriname and the Dutch Caribbean , 2016, Vox sanguinis.

[20]  E. Seifried,et al.  Recipients potentially infected with parvovirus B19 by red blood cell products , 2011, Transfusion.

[21]  D. Coulombier,et al.  Assessing the risk of a community outbreak of hepatitis A on blood safety in Latvia, 2008. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[22]  Welling Oei,et al.  Modeling the transmission risk of emerging infectious diseases through blood transfusion , 2013, Transfusion.

[23]  C. Promwong,et al.  The risk of blood transfusion–associated Chikungunya fever during the 2009 epidemic in Songkhla Province, Thailand , 2014, Transfusion.

[24]  E. Wood,et al.  Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk , 2017, Transfusion Medicine Reviews.

[25]  Marion C Lanteri,et al.  West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety , 2014, Transfusion.

[26]  F. Houston,et al.  Creutzfeldt‐Jakob disease and blood transfusion safety , 2018, Vox sanguinis.